Developments PolTREG initiates Phase 2 trial of PTG-007 targeting functional cure for children at risk of T1D PolTREG (WSE:PTG) has launched a Phase 2 clinical trial of PTG-007, a polyclonal autologous Treg cellular therapy, in children with presymptomatic Type-1 diabetes (T1D), following approval from the European Medicines... October 24, 2024